I
Power Law company profile
Immunocore
Biotech & Life Sciences · Milton, United Kingdom · Founded 2008 · IPO 2021 Unicorn
Valuation
$996M
Market cap · Apr/2026
Revenue
$402M
Latest reported FY
Global footprint
Where Immunocore has talent and traffic
AI talent share
0.3%
of workforce is AI talent
(2 of 587 staff)
(2 of 587 staff)
Core AI10.17%
Other AI10.17%
Non-AI workforce58599.66%
Web traffic by country
12K
monthly visits
across markets
across markets
🇺🇸 United States47.5%
🇬🇧 United Kingdom36.7%
🇮🇳 India7.5%
🇨🇭 Switzerland6.7%
🇩🇪 Germany0.8%
Patent intelligence
$98M patent portfolio · 59 active families
Total estimated portfolio value via Dealroom Patent Intelligence (Patsnap), with quality scores compared against same-sector peers.
Estimated portfolio value
$98M
9.8% of market cap · 72.4× smaller than top peer Janssen Vaccines ($7.1B)
59 active patent families
Where Immunocore innovates
Cellular receptorCancer researchT-cell AntigenCarcinosisPharmacology
Below peer median on Strategic, Market
Quality vs same-sector peers
Immunocore on the five Patsnap quality dimensions
Immunocore in orange. Same-sector peers are the top filers by total patent value. All scores 0–100; higher is stronger.
Compare against
Patent quality scores (0–100)
Source: Dealroom Patent Intelligence · PatsnapTech-focus vs peers
Where Immunocore concentrates inside the peer cluster
Axes are the most-shared Patsnap topics across Immunocore and its top peers. Each polygon's reach on an axis = how prominent that topic is in that company's portfolio (#1 topic = 100, #10 = 10, absent = 0).
Compare against
Top-topic prominence (rank inverted, 0–100)
Source: Dealroom Patent Intelligence · Patsnap top-10 topics per companySee Immunocore on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.